BridgeBio Oncology Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
BBOT$2.20-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34) | 116 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 117 |
| Consolidated Statements of Operations for the years ended December 31, 2025 and 2024 | 118 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025 and 2024 | 119 |
| Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the years ended December 31, 2025 and 2024 | 120 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | 121 |
| Notes to Consolidated Financial Statements | 122 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.